Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) announced on December 8, 2025 the commencement of a proposed underwritten public offering to issue and sell $500 million of American depositary shares (ADSs) or, for certain investors, pre-funded warrants to purchase ordinary shares represented by ADSs. Each ADS represents three ordinary shares. The company expects to grant underwriters a 30-day option to purchase up to an additional $75 million of ADSs or pre-funded warrants. The offering is subject to market and other conditions and may not be completed. The offering is being made under an automatic shelf registration statement on Form S-3 filed with the SEC on August 6, 2025, and a preliminary prospectus supplement will be filed and available on SEC.gov.
Positive
- $500 million proposed capital raise via ADSs or pre-funded warrants
- $75 million 30-day overallotment option granted to underwriters
Negative
- Potential shareholder dilution from the $500 million securities offering
- No assurance the proposed offering will be completed; subject to market conditions
News Market Reaction
On the day this news was published, GPCR gained 102.49%, reflecting a significant positive market reaction. Argus tracked a peak move of +156.5% during that session. Argus tracked a trough of -32.5% from its starting point during tracking. Our momentum scanner triggered 91 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $2.91B to the company's valuation, bringing the market cap to $5.76B at that time. Trading volume was exceptionally heavy at 7.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GPCR gained 5.21% while close peers showed mixed, smaller moves (e.g., ELVN +1.77%, NUVB +2.64%, PGEN -5.01%). This suggests the reaction was more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings and pipeline | Positive | +3.9% | Q3 2025 financials and pipeline timing, cash runway to at least 2027. |
| Sep 02 | Investor conferences | Positive | +4.0% | Participation in two major healthcare investor conferences and webcasts. |
| Aug 06 | Earnings and updates | Positive | -0.7% | Q2 2025 results, strong cash balance, expanded GLP‑1 clinical program. |
| Jun 20 | Clinical data update | Positive | +1.7% | Preclinical data for ACCG‑2671 and GSBR‑5595 at ADA scientific meeting. |
Recent news events have mostly seen price moves align with generally positive operational and financial updates, with one earnings report showing a mild divergence.
This announcement follows a series of updates highlighting clinical and financial progress. In Q2 2025 and Q3 2025, GPCR reported advancing its oral GLP‑1 program and amylin agonists with cash of up to $799.0M, projected to fund operations through at least 2027. A June clinical trial data update and a September conferences notice also saw generally positive reactions. Against that backdrop, today’s proposed offering leverages the company’s previously established capital markets access.
Regulatory & Risk Context
The company has an effective automatic shelf registration on Form S-3ASR filed on 2025-08-06, expiring on 2028-08-06, with recorded usage count of 0 prior to this proposed offering.
Market Pulse Summary
The stock surged +102.5% in the session following this news. A strong positive reaction aligns with GPCR’s pattern of constructive responses to key financing and pipeline updates, as seen around prior earnings and clinical milestones. The proposed $500M ADS and pre-funded warrant deal draws on an effective Form S-3ASR filed on 2025-08-06. Investors have previously rewarded the company’s robust cash position and late‑stage program visibility, though offering terms and execution risk could influence how sentiment evolves.
Key Terms
pre-funded warrants financial
automatic shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell
In connection with the proposed offering, Structure Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional
Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the proposed offering. LifeSci Capital and Citizens Capital Markets are acting as co-managers for the proposed offering.
The proposed offering is being made pursuant to an automatic shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (SEC) on August 6, 2025 and became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at www.sec.gov. The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the proposed offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including without limitation, statements concerning the timing, terms, size and completion of the proposed public offering. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, market risks and uncertainties, the completion of the public offering on the anticipated terms or at all, the grant to the underwriters of the option to purchase additional ADSs and other risk and uncertainties described in the Company’s filings with the SEC, including the Company’s latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
What is Structure Therapeutics announcing on December 8, 2025 (GPCR)?
How many ordinary shares does one GPCR ADS represent?
Is there an option to increase the size of the GPCR offering?
When was the registration statement for the GPCR offering filed and became effective?
Who are the joint book-running managers for the GPCR offering?
Where can investors find the GPCR preliminary prospectus supplement?
